Selegiline for Alzheimer's disease

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

“…The lack of a cognitive effect in moderate AD is consistent with a selegiline study in moderate-tosevere AD that showed no effect on ADAS-Cog11 or MMSE score when administered as monotherapy or in combination with alpha-tocopherol [11]. Evidence of a long-term benefit of selegiline on cognition has not been demonstrated; rather, a treatment effect has been observed only in 4-6-or 8-17-week studies [25]. Together, these studies suggest that MAO-Bis, when administered on top of background therapy in patients with moderate AD, do not provide cognitive benefit.…”

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

“…The lack of a cognitive effect in moderate AD is consistent with a selegiline study in moderate-tosevere AD that showed no effect on ADAS-Cog11 or MMSE score when administered as monotherapy or in combination with alpha-tocopherol [11]. Evidence of a long-term benefit of selegiline on cognition has not been demonstrated; rather, a treatment effect has been observed only in 4-6-or 8-17-week studies [25]. Together, these studies suggest that MAO-Bis, when administered on top of background therapy in patients with moderate AD, do not provide cognitive benefit.…”

Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews

“…The study selection process is presented in figure 1 (PRISMA). There were 23 systematic reviews meeting all inclusion criteria and included in this overview 13–35. An additional 10 reviews were identified that listed ADL as an outcome of interest; however the reviews failed to identify any applicable studies.…”

The Course of Primary Progressive Aphasia Diagnosis : A Cross-Sectional Study.

“…Indeed, clinical trials on patients with FTD and controlled trials on PPA patients with bromocriptine[28] and memantine [29] have not demonstrated any e ciency. Studies on limited patient samples with, galantamine, rivastigmine, and selegiline have shown no results [30]. Also, although some patients with PPA, particularly with a logopenic subtype, may suffer from atypical AD, cholinesterase inhibitors have shown no results.…”

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

“…The lack of a cognitive effect in moderate AD is consistent with a selegiline study in moderate-tosevere AD that showed no effect on ADAS-Cog11 or MMSE score when administered as monotherapy or in combination with alpha-tocopherol [11]. Evidence of a long-term benefit of selegiline on cognition has not been demonstrated; rather, a treatment effect has been observed only in 4-6-or 8-17-week studies [25]. Together, these studies suggest that MAO-Bis, when administered on top of background therapy in patients with moderate AD, do not provide cognitive benefit.…”

Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews

“…The study selection process is presented in figure 1 (PRISMA). There were 23 systematic reviews meeting all inclusion criteria and included in this overview 13–35. An additional 10 reviews were identified that listed ADL as an outcome of interest; however the reviews failed to identify any applicable studies.…”

The Course of Primary Progressive Aphasia Diagnosis : A Cross-Sectional Study.

“…Indeed, clinical trials on patients with FTD and controlled trials on PPA patients with bromocriptine[28] and memantine [29] have not demonstrated any e ciency. Studies on limited patient samples with, galantamine, rivastigmine, and selegiline have shown no results [30]. Also, although some patients with PPA, particularly with a logopenic subtype, may suffer from atypical AD, cholinesterase inhibitors have shown no results.…”

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

“…The lack of a cognitive effect in moderate AD is consistent with a selegiline study in moderate-tosevere AD that showed no effect on ADAS-Cog11 or MMSE score when administered as monotherapy or in combination with alpha-tocopherol [11]. Evidence of a long-term benefit of selegiline on cognition has not been demonstrated; rather, a treatment effect has been observed only in 4-6-or 8-17-week studies [25]. Together, these studies suggest that MAO-Bis, when administered on top of background therapy in patients with moderate AD, do not provide cognitive benefit.…”

Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews

“…The study selection process is presented in figure 1 (PRISMA). There were 23 systematic reviews meeting all inclusion criteria and included in this overview 13–35. An additional 10 reviews were identified that listed ADL as an outcome of interest; however the reviews failed to identify any applicable studies.…”

The Course of Primary Progressive Aphasia Diagnosis : A Cross-Sectional Study.

“…Indeed, clinical trials on patients with FTD and controlled trials on PPA patients with bromocriptine[28] and memantine [29] have not demonstrated any e ciency. Studies on limited patient samples with, galantamine, rivastigmine, and selegiline have shown no results [30]. Also, although some patients with PPA, particularly with a logopenic subtype, may suffer from atypical AD, cholinesterase inhibitors have shown no results.…”